These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7179418)

  • 1. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana.
    Alexander J
    Trans R Soc Trop Med Hyg; 1982; 76(5):646-9. PubMed ID: 7179418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J; Kaye PM
    Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge.
    Rivier D; Shah R; Bovay P; Mauel J
    Parasite Immunol; 1993 Feb; 15(2):75-84. PubMed ID: 8446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
    Alexander J; Coombs GH; Mottram JC
    J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between delayed hypersensitivity, lymphocyte activation and protective immunity in experimental murine leishmaniasis.
    De Rossell RA; Bray RS; Alexander J
    Parasite Immunol; 1987 Jan; 9(1):105-15. PubMed ID: 3562057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences and cross-immunity in DBA/2 mice infected with L. mexicana and L. major.
    Alexander J
    Parasitology; 1988 Apr; 96 ( Pt 2)():297-302. PubMed ID: 3374966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection.
    Mitchell GF; Handman E; Spithill TW
    Aust J Exp Biol Med Sci; 1984 Apr; 62 ( Pt 2)():145-53. PubMed ID: 6466205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
    Connell ND; Medina-Acosta E; McMaster WR; Bloom BR; Russell DG
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11473-7. PubMed ID: 8265576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
    Schmidt-Ott R; Klenner T; Overath P; Aebischer T
    Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania infecting man and wild animals in Saudi Arabia. 8. The influence of prior infection with Leishmania arabica on challenge with L. major in man.
    Peters W; Bryceson A; Evans DA; Neal RA; Kaye P; Blackwell J; Killick-Kendrick R; Liew FY
    Trans R Soc Trop Med Hyg; 1990; 84(5):681-9. PubMed ID: 2126153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines.
    Daneshvar H; Coombs GH; Hagan P; Phillips RS
    J Infect Dis; 2003 May; 187(10):1662-8. PubMed ID: 12721947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.
    Inocêncio da Luz RA; Vermeersch M; Deschacht M; Hendrickx S; Van Assche T; Cos P; Maes L
    J Antimicrob Chemother; 2011 Feb; 66(2):350-3. PubMed ID: 21131319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential phagocytosis of Leishmania mexicana promastigotes and amastigotes by monocyte-derived dendritic cells.
    Argueta-Donohué J; Wilkins-Rodríguez AA; Aguirre-García M; Gutiérrez-Kobeh L
    Microbiol Immunol; 2016 Jun; 60(6):369-81. PubMed ID: 26399218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ox40L-Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major.
    Tuladhar R; Oghumu S; Dong R; Peterson A; Sharpe AH; Satoskar AR
    Exp Parasitol; 2015 Jan; 148():49-55. PubMed ID: 25447125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophoretic analysis of the polypeptides of Leishmania amastigotes and promastigotes.
    Pupkis MF; Coombs GH
    Comp Biochem Physiol B; 1986; 83(3):629-32. PubMed ID: 3956174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
    Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
    Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania amastigotes: resistance to complement-mediated lysis is not due to a failure to fix C3.
    Mosser DM; Wedgwood JF; Edelson PJ
    J Immunol; 1985 Jun; 134(6):4128-31. PubMed ID: 3886796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.